{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:04Z","timestamp":1787029324718,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA193967-05"],"award-info":[{"award-number":["5R01CA193967-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA122558-05"],"award-info":[{"award-number":["5R01CA122558-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Non-muscle-invasive bladder cancer (NMIBC) has one of the highest recurrence rates among all solid cancers and the highest lifetime treatment cost per patient. Therefore, the development of chemoprevention strategies for reducing the occurrence and recurrence of NMIBC as well as its burdens on the healthcare system is valuable. Our aim was to determine whether flavokawain A (FKA), a kava chalcone isolated from the kava plant, can target the in vivo activated Ha-ras pathway for prevention and treatment of NMIBC. UPII-mutant Ha-ras transgenic mice that develop papillary urothelial cell carcinoma were fed orally with vehicle control or FKA-formulated food for 6 months starting at 6 weeks of age. Seventy-nine percent (15\/19) of male mice fed with 6 g FKA per kilogram (kg) of food survived beyond the 6 months of treatment, while 31.6% (6\/19) of control food-fed male mice survived the 6-month treatment period (p = 0.02). The mean bladder weights in FKA vs. control food-fed mice were 0.216 \u00b1 0.033 vs. 0.342 \u00b1 0.039 g in male mice (p = 0.0413) and 0.043 \u00b1 0.004 vs. 0.073 \u00b1 0.004 g in female mice (p &lt; 0.0001); FKA reduced bladder weight by 37% and 41%, respectively. The tumor burdens, determined by the wet bladder weight, in these mice were inversely related to plasma FKA concentrations. In addition to decreased bladder weight, FKA treatment significantly reduced the incidences of hydronephrosis and hematuria. FKA-treated mice exhibited more well-differentiated tumors in the bladder and ureter. Immunohistochemical analysis of FKA-treated tumors compared to those in the control group revealed fewer Ki-67- and survivin-positive cells and an increased number of p27- and TUNEL-positive cells, indicating that FKA inhibits proliferation and induces apoptosis. Overall, the results suggest that FKA can target the in vivo activated Ha-ras pathway for the prevention and treatment of NMIBC.<\/jats:p>","DOI":"10.3390\/pharmaceutics14030496","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T21:11:07Z","timestamp":1645737067000},"page":"496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chemoprevention of Urothelial Cell Carcinoma Tumorigenesis by Dietary Flavokawain A in UPII-Mutant Ha-ras Transgenic Mice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-1261","authenticated-orcid":false,"given":"Zhongbo","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liankun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Simoneau","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Uchio","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"},{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine, CA 92868, USA"},{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92868, USA"},{"name":"Department of Pharmaceutical Sciences, University of California, Irvine, CA 92617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"ref_1","unstructured":"(2021, December 21). Bladder Cancer Key Statistics. Available online: https:\/\/www.cancer.net\/cancer-types\/bladder-cancer\/statistics."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: What are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e213800","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","article-title":"Urothelial tumorigenesis: A tale of divergent pathways","volume":"5","author":"Wu","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI30062","article-title":"Hyperactivation of Ha-ras oncogene, but not Ink4a\/Arf deficiency, triggers bladder tumorigenesis","volume":"117","author":"Mo","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-04-3803","article-title":"Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice","volume":"65","author":"Zi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_8","first-page":"420","article-title":"The correlation between cancer incidence and kava consumption","volume":"59","author":"Steiner","year":"2000","journal-title":"Hawaii Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113582","DOI":"10.1016\/j.jep.2020.113582","article-title":"Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop","volume":"268","author":"Thomsen","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1940-6207.CAPR-08-0165","article-title":"Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53","volume":"1","author":"Tang","year":"2008","journal-title":"Cancer Prev. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1158\/1940-6207.CAPR-13-0219","article-title":"Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model","volume":"6","author":"Liu","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Minoli, M., Kiener, M., Thalmann, G.N., Kruithof-de Julio, M., and Seiler, R. (2020). Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165670"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1535-7163.MCT-15-0714-T","article-title":"High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with 240-Fold Higher Drug Concentration in Urine than Serum","volume":"15","author":"Liu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.urolonc.2019.12.010","article-title":"A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria","volume":"38","author":"Matulewicz","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrurol.2011.96","article-title":"Prognostic factors for upper urinary tract urothelial carcinoma","volume":"8","author":"Chromecki","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: Non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1021\/acs.jafc.5b01858","article-title":"Biotransformation of Flavokawains A, B, and C, Chalcones from Kava (Piper methysticum), by Human Liver Microsomes","volume":"63","author":"Zenger","year":"2015","journal-title":"J. Agric. Food Chem."},{"key":"ref_18","first-page":"809","article-title":"Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder","volume":"62","author":"Hartmann","year":"2002","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"Iyer","year":"2011","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Abu, N., Akhtar, M.N., Yeap, S.K., Lim, K.L., Ho, W.Y., Zulfadli, A.J., Omar, A.R., Sulaiman, M.R., Abdullah, M.P., and Alitheen, N.B. (2014). Flavokawain A induces apoptosis in MCF-7 and MDA-MB231 and inhibits the metastatic process in vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105244"},{"key":"ref_21","first-page":"3512","article-title":"Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma","volume":"59","author":"Zhang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jandial, D.D., Krill, L.S., Chen, L., Wu, C., Ke, Y., Xie, J., Hoang, B.H., and Zi, X. (2017). Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin. Molecules, 22.","DOI":"10.20944\/preprints201701.0098.v1"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nakajima, E.C., Drezner, N., Li, X., Mishra-Kalyani, P.S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., and Wearne, E. (Clin. Cancer Res., 2021). FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC, Clin. Cancer Res., Online ahead of print.","DOI":"10.1158\/1078-0432.CCR-21-3074"},{"key":"ref_24","first-page":"725","article-title":"HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer","volume":"53","author":"Sugita","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14712598.2021.1865910","article-title":"Enfortumab vedotin\u2014Next game-changer in urothelial cancer","volume":"21","author":"Maas","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1940-6207.CAPR-19-0339","article-title":"Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers","volume":"13","author":"Mohammed","year":"2020","journal-title":"Cancer Prev. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","article-title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer","volume":"39","author":"Rose","year":"2020","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.toxrep.2014.02.002","article-title":"Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice","volume":"1","author":"Li","year":"2014","journal-title":"Toxicol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41809","DOI":"10.18632\/oncotarget.6166","article-title":"Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/3\/496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:26:40Z","timestamp":1760135200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/3\/496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["pharmaceutics14030496"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14030496","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}